Pharmacokinetics of Salmeterol Via HandiHaler® in Healthy Male Volunteers
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate if the systemic drug exposure of at least 25 μg
and perhaps 50 μg salmeterol presented as inhalation powder in PE capsules and administered
via HandiHaler® 2 does not exceed that of 50 μg Serevent® Diskus® and to investigate safety
and tolerability of salmeterol presented as inhalation powder in PE capsules and administered
via HandiHaler® 2